最新ニュース Medtronic (NYSE:MDT) 株価情報

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Bernstein analyst Lee Hambright maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $96 to $97.

News

Price Target

Analyst Ratings

Bernstein Maintains Outperform on Medtronic, Raises Price Target to $97

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and lowers the price target from $106 to $98.

Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $98

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.
GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic&nbsp;plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen&#x2122; app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera&#x2122; continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen&#x2122; smart insulin pen with its newest Simplera&#x2122; CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.
With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection (MDI) therapy.&nbsp;

Biotech

General

Medtronic Receives FDA Clearance For New InPen App, Paving The Way For Its Smart MDI System Launch With Simplera CGM

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and lowers the price target from $96 to $93.

Baird Maintains Neutral on Medtronic, Lowers Price Target to $93

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Medtronic

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Tuesday.
U.S. stocks settled mixed on Tuesday, with the Nasdaq gaining around 1% during the session as investors shrugged off rising geopolitical concerns between Ukraine and Russia. Ukraine launched its first U.S.-made missile strike on a Russian city, while Russian President Vladimir Putin adjusted the nation&#8217;s nuclear doctrine to broaden scenarios for a potential response.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares gained around 5% on Tuesday ahead of its quarterly earnings report, due to be released today. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares also gained 2%, adding around 38% month-to-date.
Shares of Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) rose around 3% on Tuesday after the company posted upbeat quarterly earnings and raised its outlook. Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raised its outlook.
On the economic data front, housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month. U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, communication services, and consumer discretionary stocks recording the biggest gains on Monday. However, industrials stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed lower by around 121 points to 43,268.94 on Tuesday. The S&amp;P 500 rose 0.40% to 5,916.98, while the Nasdaq Composite gained 1.04% to close at 18,987.47 during Tuesday's session.
Investors are awaiting earnings results from Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.1, the index remained in the &#8220;Neutral&#8221; zone on Tuesday, versus a prior reading of 49.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Markets

Trading Ideas

NVDA

TSLA

Nasdaq Gains 1% Ahead Of Nvidia Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&amp;P 500 also rose, gaining, 0.49% to 5,922.41.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Tuesday.
In trading on Tuesday, materials shares fell by 0.6%.
Top Headline
Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raise its outlook.
The company posted second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%. Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 29% to $27.84 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 172% to $1.4600. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 30% to $3.30. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 13% to $66.74 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 11% to $6.77 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.12 while gold traded up 0.7% at $2,632.40.
Silver traded up 0.3% to $31.305 on Tuesday, while copper rose 0.6% to $4.1435.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.45%, Germany's DAX fell 0.67% and France's CAC 40 fell 0.67%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.13%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

CDRO

INCY

NWTN

PRFX

SMCI

TRNR

Gold Moves Higher; Medtronic Posts Upbeat Results

Tuesday,&nbsp;Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported second-quarter 2025 sales of $8.40 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.27 billion</a>. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Revenue increased 5.3% year over year, as reported,&nbsp;and 5% on an organic basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41184951/medtronic-recalls-minimed-pump-due-to-battery-life-concerns" rel="noreferrer noopener">Medtronic Recalls MiniMed Pump Due To Battery Life Concerns</a>
Cardiovascular segment revenue reached&nbsp;$3.102 billion, up 6.1% year over year as reported, and&nbsp;increased 5.6% organically, &nbsp;with a high-single-digit increase in Structural Heart &amp; Aortic and mid-single-digit increases in &nbsp;Cardiac Rhythm &amp; Heart Failure and Coronary &amp; Peripheral Vascular, all <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42058326/medtronic-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">on an organic basis</a>.
Neuroscience revenues of&nbsp;$2.45 billion&nbsp;increased 7.1% as reported and 6.7% organically, with a low-double-digit increase in Neuromodulation and mid-single-digit increases in Cranial &amp; Spinal Technologies and Specialty Therapies, all on an organic basis.
Medical Surgical&nbsp;revenue of&nbsp;$2.13 billion&nbsp;increased by 1.2% as reported and increased by 0.7% organically, with a low-single-digit organic increase in Acute Care &amp; Monitoring and flat organic result in Surgical &amp; Endoscopy.
Surgical &amp; Endoscopy year-over-year results were affected by a difficult comparison from the prior year supply recovery in Surgical and increased high-single digits sequentially.
Diabetes revenue of&nbsp;$686 million&nbsp;increased by 12.4%, as reported, and by 11% organic.
&#8220;Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations,&#8221; said&nbsp;Geoff Martha, Medtronic chairman and chief executive officer.
Guidance:&nbsp;Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40462317/medical-devices-giant-medtronic-q1-earnings-revenue-and-eps-beat-lifts-annual-guidance-marginally-o" rel="noreferrer noopener">from the prior 4.5%-5%</a>.
If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.
Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Price Action: MDT stock is down 3.52% at $84.53 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" target="_blank" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a></li>
</ul>
Photo by Tony Webster via <a href="https://commons.wikimedia.org/wiki/File:Medtronic_Headquarters_Office_Building_-Mounds_View,_Minnesota(43381897454).jpg">Wikimedia Commons</a>

Large Cap

Guidance

Health Care

Movers

Medtronic Q2 Earnings: Diabetes And Neuroscience Revenue Boost Growth, Raises Annual Outlook

Medtronic shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales and raised its FY25 guidance.

The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.44 to $5.50 versus the prior $5.42 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates, unchanged from the prior guidance. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.

Medtronic Raised Its Fy25 Adjusted EPS Guidance To $5.44-$5.50 Versus The Prior $5.42-$5.50 And Consensus Of $5.45

The company raised its FY25 organic revenue growth guidance to 4.75% to 5% versus the prior range of 4.5% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on an adjusted basis would be in the range of 3.4% to 3.9%.

Medtronic Raised Its FY25 Organic Revenue Growth Guidance To 4.75%-5% Versus The Prior Range Of 4.5%-5%

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.25 by 0.8 percent. The company reported quarterly sales of $8.40 billion which beat the analyst consensus estimate of $8.27 billion by 1.59 percent. This is a 5.25 percent increase over sales of $7.98 billion the same period last year.

Medtronic Q2 2025 Adj EPS $1.26 Beats $1.25 Estimate, Sales $8.40B Beat $8.27B Estimate

U.S. stocks could open on a negative note on Tuesday after the <a href="https://www.benzinga.com/news/econ-s/24/11/42017118/stocks-tumble-as-traders-rethink-feds-action-vix-spikes-17-nasdaq-erases-back-post-trump-gains-whats-driving-markets-friday">averages maintained a cautious stance last week</a>. Futures of all three major indices were slightly down on Tuesday, pointing to a cautious sentiment on Wall Street.
Economic data and Federal Reserve chair Jerome Powell's comments about the future of rate cuts dampened the sentiment. Powell said the Federal Open Market Committee (FOMC) is not in a hurry after economic data showed strength.
Geopolitical tensions are weighing on investor sentiment, as Russian President Vladimir Putin expanded the country's nuclear doctrine, according to reports <a href="https://tass.com/politics/1874437">by</a> the TASS news agency.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.36%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.47%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.62%</td>
</tr>
<tr>
<td>R2K</td>
<td>-1.29%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.35% to $586.11 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 0.29% to $498.58, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks closed on a mixed note on Monday, with the Dow Jones closing in the red while the Nasdaq and S&amp;P 500 edged up.
Crude oil prices remained under the $70 mark, edging lower after rebounding due to disruptions in Norway.
Treasury yields eased marginally amid a broader risk-off sentiment.
On the economic data front, the NAHB/Wells Fargo Housing Market Index climbed to 46 in November from 43 in October, recording the highest reading in seven months.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, communication services, and consumer discretionary stocks recording the biggest gains on Monday.
However, industrial stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.60%</td>
<td>18,791.81</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.39%</td>
<td>5,893.62</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.13%</td>
<td>43,389.60</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.11%</td>
<td>2,306.34</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Tom Lee, head of research at FundStrat Global Advisors, noted <a href="https://www.cnbc.com/video/2024/11/18/watch-cnbcs-full-interview-with-fundstrat-global-advisors-tom-lee.html">in</a> an interview with CNBC that the "Trump trade" is still intact despite it losing some steam over the past week.
He underscored that as uncertainty reduces around President-elect Donald Trump's announcement of Treasury Secretary, it will be a "clearing event" for the markets.
He also believes that although Fed chair Powell said there is no need to rush with rate cuts, the expectations for the number of cuts over the next year remain the same. Essentially, it's only a matter of timing, according to Lee.
With Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) set to announce its results this week, Lee thinks that it will be another "clearing event" for the markets.
"Markets get very hesitant in front of Nvidia's earnings. Once that is behind us, we'll see that the demand is strong and I think markets breathe a sigh of relief."
WisdomTree and Wharton School economist&nbsp;Jeremy Siegel reiterated his bull thesis but noted that higher rates could lead to some volatility in the near term.
"Equities still offer superior returns over the longer term compared to bonds," he said, as investors turn their eye towards the Federal Open Market Committee's (FOMC) next meeting.
Expectations of a further 25 basis point rate cut in December have fallen to just 65% now, down from 72% last week, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
"With long-term rates climbing, the market's trajectory will depend heavily on not only economic data but a clarification Trump's policies on tariffs and deportations," Siegel said.
On the whole, the Wharton economist underscored that "companies with strong balance sheets and pricing power" are best positioned to weather this higher-rate environment.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Tuesday's economic calendar is fairly light.
<ul>
<li>Data on new home construction and building permits will be released at 8:30 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee&nbsp;will speak at 12:25 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares continued to rally, gaining 5.6% on Monday amid reports of Trump's transition team <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">looking to ease self-driving rules</a>.</li>
<li>Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) subsidiary Google is staring at the prospect of <a href="https://www.benzinga.com/news/legal/24/11/42053249/google-could-lose-chrome-browser-in-dojs-latest-antitrust-move">divesting the Chrome web browser</a> as part of the Department of Justice's (DOJ) latest antitrust move. The company's stock fell in <a href="https://www.benzinga.com/markets/24/11/42056544/googles-parent-alphabet-shares-dip-during-tuesday-pre-market-whats-going-on">premarket trading on Tuesday</a>.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares <a href="https://www.benzinga.com/markets/equities/24/11/42057634/super-micro-computer-is-up-by-30-on-tuesday-pre-market-whats-going-on">surged over 30% in premarket trading on Tuesday</a> after the company submitted a compliance plan to continue trading on the Nasdaq.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares were down 4.7% in premarket trading after <a href="https://www.benzinga.com/general/social-media/24/11/42048594/trump-digs-deeper-into-cryptocurrency-bakkt-shares-soar-on-reported-interest-from-president-elects-media-company">reports suggested</a> that it is looking to acquire cryptocurrency company Bakkt Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>).</li>
<li>Investors are awaiting earnings results from Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), and Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures surged in the early New York session, falling by 0.7% to hover around $68.69 per barrel.
The 10-year Treasury note yield eased marginally to 4.365%.
Major Asian markets ended in the green on Tuesday, while European stocks declined in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways">Jim Cramer Thinks Trump&#8217;s Plans For Robotaxis Are &#8216;Fanciful,&#8217; But He Is Still Bullish On Tesla Stock: &#8216;The Musk Premium Will Work Its Magic In Other Ways&#8217;</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Economics

Federal Reserve

Bakkt Holdings, Inc. Class A Common Stock

BKKT

GOOG

GOOGL

US Stocks Likely To Open In Red Amid Mounting Geopolitical Tensions: Wharton Economist Says Market Trajectory Will 'Heavily Depend' On Trump's Tariff Plans

<h3>Companies Reporting Before The Bell</h3>
• Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) is likely to report quarterly loss at $0.32 per share on revenue of $13.15 million. 
• EuroDry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDRY#NASDAQ">EDRY</a>) is projected to report quarterly loss at $0.23 per share on revenue of $19.14 million. 
• S&amp;W Seed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is expected to report quarterly loss at $1.40 per share on revenue of $17.00 million. 
• GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.21 per share on revenue of $415.42 million. 
• Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) is expected to report quarterly earnings at $0.42 per share on revenue of $432.47 million. 
• Energizer Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENR#NYSE">ENR</a>) is likely to report quarterly earnings at $1.17 per share on revenue of $805.43 million. 
• Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) is likely to report quarterly earnings at $1.37 per share on revenue of $3.01 billion. 
• Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is likely to report quarterly loss at $0.14 per share on revenue of $247.64 million. 
• Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $264.74 million. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $203.93 million. 
• Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) is expected to report quarterly earnings at $2.82 per share on revenue of $19.94 billion. 
• Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.91 billion. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $435.98 million. 
• Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) is estimated to report quarterly earnings at $0.53 per share on revenue of $167.72 billion. 
• Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) is expected to report quarterly earnings at $0.85 per share on revenue of $1.66 billion. 
• Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is likely to report quarterly loss at $0.20 per share on revenue of $8.57 million. 
• Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $22.50 million. 
• Eltek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTK#NASDAQ">ELTK</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $12.40 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is expected to report quarterly earnings at $0.97 per share on revenue of $347.63 million. 
• Allot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $22.80 million. 
• Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is likely to report quarterly earnings at $1.86 per share on revenue of $1.61 billion. 
• XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $1.38 billion. 
• Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $1.30 billion. 
• Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is projected to report quarterly earnings at $1.25 per share on revenue of $8.27 billion. 
• Oaktree Specialty Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $96.90 million. 
<h3>Companies Reporting After The Bell</h3>
• Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is projected to report quarterly loss at $0.82 per share on revenue of $4.68 million. 
• XP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XP#NASDAQ">XP</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $772.20 million. 
• AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $339.99 million. 
• Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) is estimated to report earnings for its third quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $1.09 billion. 
• StoneX Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNEX#NASDAQ">SNEX</a>) is estimated to report quarterly earnings at $2.05 per share on revenue of $462.98 million. 
• Kore Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) is estimated to report quarterly loss at $0.63 per share on revenue of $67.90 million. 
• ReNew Energy Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNW#NASDAQ">RNW</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $313.59 million. 
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is likely to report quarterly earnings at $1.42 per share on revenue of $588.49 million. 
• Star Bulk Carriers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>) is expected to report quarterly earnings at $0.99 per share on revenue of $305.05 million. 
• Powell Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) is likely to report quarterly earnings at $3.55 per share on revenue of $286.49 million. 
• La-Z-Boy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LZB#NYSE">LZB</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $505.98 million. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $297.67 million. 
• Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $200.54 million. 
• Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) is likely to report quarterly earnings at $1.57 per share on revenue of $1.26 billion. 
• ZTO Express (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $1.48 billion. 
• Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is estimated to report quarterly earnings at $0.70 per share on revenue of $307.94 million. 
• Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) is expected to report quarterly earnings at $0.44 per share on revenue of $234.39 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLT

ATAT

AUNA

AZEK

DNMR

EDRY

ELTK

ESLT

FUTU

GBDC

KEYS

KORE

MYTE

NTIC

OCSL

POWL

QFIN

RIME

SANW

SBLK

SNEX

STRR

VIPS

VREX

WKHS

XPEV

Earnings Scheduled For November 19, 2024

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Monday.
U.S. stocks settled mixed on Monday, with the Nasdaq gaining more than 100 points during the session as the Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock surged 5.6% following reports of President-elect Donald Trump&#8217;s <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">policy outlook on regulations for autonomous driving</a>.
U.S. stocks recorded losses last week, with the S&amp;P 500 falling 2.1% and the Nasdaq Composite losing around 3.2%. The 30-stock Dow lost 1.2% during the week.
As far as the earnings season is concerned, around 93% of the S&amp;P 500 companies have released quarterly results so far, with around 74% of those exceeding earnings estimates.
On the economic data front, the NAHB/Wells Fargo Housing Market Index climbed to 46 in November, recording the highest reading in seven months, compared to 43 in October.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, communication services, and consumer discretionary stocks recording the biggest gains on Monday. However, industrials stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed lower by around 55 points to 43,389.60 on Monday. The S&amp;P 500 rose 0.39% to 5,893.62, while the Nasdaq Composite gained 0.60% to close at 18,791.81 during Monday's session.
Investors are awaiting earnings results from Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), and Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.1, the index remained in the &#8220;Neutral&#8221; zone on Monday, versus a prior reading of 51.1.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Nasdaq Gains Over 100 Points As Tesla Surges: Investor Sentiment Declines, Fear & Greed Index Remains In 'Neutral' Zone

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) to report quarterly earnings at 53 cents per share on revenue of $167.72 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Walmart shares rose 1.6% to $85.44 in after-hours trading.</li>
<li>AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) reported better-than-expected earnings for its fourth quarter. The company's quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion. Aecom shares fell 1.2% to $107.80 in the after-hours trading session.</li>
<li>Analysts expect Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) to post quarterly earnings at $2.82 per share on revenue of $19.94 billion. The company will release earnings before the markets open. Lowe&#8217;s shares gained 0.1% to $272.10 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported better-than-expected results for its fourth quarter on Monday. For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million. Symbotic shares jumped 26.3% to $38.60 in the after-hours trading session.</li>
<li>Analysts expect Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) to report quarterly earnings at $1.25 per share on revenue of $8.27 billion before the opening bell. Medtronic shares gained 0.2% to $87.74 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>
Image via Wikimedia Commons

Walmart, Lowe's And 3 Stocks To Watch Heading Into Tuesday

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-19. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Medtronic will report an earnings per share (EPS) of $1.25.
Investors in Medtronic are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 2.53% increase in the share price the next day.
Here's a look at Medtronic's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.45</td>
<td>1.26</td>
<td>1.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.23</td>
<td>1.46</td>
<td>1.30</td>
<td>1.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>1.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731949231_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Medtronic were trading at $87.53 as of November 15. Over the last 52-week period, shares are up 12.07%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Medtronic</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Medtronic.
A total of 13 analyst ratings have been received for Medtronic, with the consensus rating being Neutral. The average one-year price target stands at $95.85, suggesting a potential 9.51% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Boston Scientific, Stryker and Becton Dickinson, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Boston Scientific is favoring an Buy trajectory, with an average 1-year price target of $96.63, suggesting a potential 10.4% upside.</li>
<li>Stryker received a Outperform consensus from analysts, with an average 1-year price target of $395.16, implying a potential 351.46% upside.</li>
<li>As per analysts' assessments, Becton Dickinson is favoring an Buy trajectory, with an average 1-year price target of $282.5, suggesting a potential 222.75% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Boston Scientific, Stryker and Becton Dickinson, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic</td>
<td>Neutral</td>
<td>2.77%</td>
<td>$5.15B</td>
<td>2.12%</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>Buy</td>
<td>19.34%</td>
<td>$2.90B</td>
<td>2.28%</td>
</tr>
<tr>
<td>Stryker</td>
<td>Outperform</td>
<td>11.92%</td>
<td>$3.52B</td>
<td>4.18%</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>Buy</td>
<td>8.96%</td>
<td>$2.31B</td>
<td>1.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Medtronic ranks in the middle among its peers for revenue growth. It is at the bottom for gross profit and return on equity.
<h3>Delving into Medtronic's Background</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Financial Milestones: Medtronic's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Medtronic displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 2.77%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 13.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Medtronic's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.12%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Medtronic's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average. With a ratio of 0.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/MDT/earnings">To track all earnings releases for Medtronic visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Medtronic

Across the recent three months, 13 analysts have shared their insights on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $95.85, along with a high estimate of $106.00 and a low estimate of $87.00. This current average reflects an increase of 4.28% from the previous average price target of $91.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1731931210_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$93.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Medtronic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>Get to Know Medtronic Better</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>A Deep Dive into Medtronic's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Medtronic's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.12%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Medtronic's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.58.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Medtronic's Future

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

Piper Sandler Issues a Hold Rating on Medtronic (MDT)

Baird analyst David Rescott lowered the firm's price target on Medtronic (MDT) to $93 from $96 and keeps a Neutral rating on the shares. The firm s...

Medtronic price target lowered to $93 from $96 at Baird

Bernstein raised the firm's price target on Medtronic (MDT) to $97 from $96 and keeps an Outperform rating on the shares. The firm notes revenue gr...

Medtronic price target raised to $97 from $96 at Bernstein

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Medtronic (MDT) announced FDA clearance for its new InPen app featuring missed meal dose detection, paving the way for the launch of its Smart MDI ...

Medtronic announces FDA clearance for its new InPen app

Stifel Nicolaus analyst Rick Wise maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of $87.00. The company...

Stifel Nicolaus Sticks to Their Hold Rating for Medtronic (MDT)

Medtronic receives FDA clearance for new InPen app

SA Charts: These S&P 500 companies spent the largest on buybacks last quarter

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Medtronic (MDT – Research Report) yesterday and set a price target of $105.00. T...

Medtronic (MDT) Receives a Buy from RBC Capital

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Applied Therapeutics (APLT – Research Report) and Me...

Wall Street Analysts Are Bullish on Top Healthcare Picks

AAPL

ABBV

ADBE

AGNC

ALIZF

APLT

ARCC

AVGO

BABA

BASFY

BAYZF

BLUE

BXSL

CBAUF

CSCO

CSWC

GAIN

GILD

GLAD

GOOD

GSBD

HTGC

INTC

MAIN

MFIC

MNST

MSFT

NEWT

OBDC

RITM

SEMHF

SHEL

STAG

STWD

TMUS

UNIT

XLRE

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life

A new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter

SPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter

Medtronic to announce financial results for its second quarter of fiscal year 2025

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Medtronic reports second quarter fiscal 2025 financial results

Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential

Comments

Medtronic

ニュース

最新ニュース Medtronic (NYSE:MDT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル